Bone Cement - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Bone cement market size in 2026 is estimated at USD 1.23 billion, growing from 2025 value of USD 1.17 billion with 2031 projections showing USD 1.61 billion, growing at 5.44% CAGR over 2026-2031. This report is Segmented by Product Type (Polymethyl Methacrylate Cement, Calcium Phosphate Cement, Glass Polyalkenoate Cement, Calcium-Sulphate-Based Cement), Viscosity (Low, Medium, High), Application (Arthroplasty, Vertebroplasty, Kyphoplasty, and More), End-User (Hospitals, Orthopaedic Clinics, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Bone Cement Market Trends and Insights

Ageing-Related Arthroplasty Volumes Rising Sharply

Populations aged 65 and older are growing faster than any other demographic, and they increasingly seek mobility-restoring surgeries instead of living with disability. The rise reflects new anesthesia protocols, more durable implants, and value-based payment models that favor early intervention. Sustained procedure volumes translate directly into repeat demand for cement, especially in elderly bones of lower density that benefit from PMMA’s immediate fixation. Longer life expectancy also increases the pool of revision cases, further amplifying cement consumption. Collectively, these demographic and clinical shifts add roughly 1.8 percentage points to forecast CAGR.

Sports & Road-Traffic Trauma Boosting Revision Surgeries

Greater recreational sports participation and urban congestion elevate high-energy injury rates, driving revision orthopedics. The United States reported more than 7 million orthopedic injuries and 1.1 million emergency surgeries in a single year, with complex trauma requiring larger cement volumes for bone void filling. High-grade fractures often entail staged fixation and augmentative cement, multiplying unit consumption per patient. Emerging economies mirror this trend as motorcycle ownership surges and road-safety enforcement lags. The aggregate effect lifts bone cement market growth by an estimated 1.2 percentage points through mid-decade.

Stringent FDA & MDR Approval Timelines

Regulatory complexity surrounding bone cement modifications and new formulations is creating significant barriers to innovation and market entry. Special 510(k) pathways still require exhaustive bench testing data, and Europe’s MDR demands more clinical evidence, delaying launches by up to 18 months and adding significant pre-market costs. These regulatory hurdles disproportionately impact smaller companies and innovative startups that lack the resources to navigate complex approval processes, potentially stifling competition and technological advancement in the bone cement sector. The net effect drags the bone cement market expansion by 1.2 percentage points during the medium term.

Other drivers and restraints analyzed in the detailed report include:

• Surge in Antibiotic-Laden Cement to Curb Post-Operative Infections
• Outpatient Joint-Replacement Expansion in ASCs
• High Exothermic Polymerisation Causing Thermal Necrosis Risk

Segment Analysis

PMMA maintained a commanding 72.10% bone cement market share in 2025 on the strength of long-term survivorship data and surgeon familiarity. The segment’s reliability keeps procurement departments aligned with legacy vendors, anchoring hospital formularies. Recent innovations, such as nano-tantalum carbide doping, improve radiopacity without undermining biomechanics. Yet calcium-phosphate cement is projected to post a 6.63% CAGR as orthopedic oncologists and trauma surgeons adopt its osteoconductive chemistry to accelerate bone integration. Glass-polyalkenoate cements find footholds in dental and craniofacial repairs where fluoride release is beneficial, while calcium-sulfate blends satisfy niche infection-management needs through resorbability.

Reimbursement revisions that reward faster union and fewer re-operations favor bioactive alternatives. However, scale economies, mature supply chains, and easier storage conditions preserve PMMA’s lead in the bone cement market. Continued R&D inside the conventional chemistry - such as low-monomer, high-viscosity variants - aims to extend PMMA’s lifecycle. The bone cement industry nevertheless perceives product diversification as inevitable, with first-mover brands positioning dual portfolios that marry PMMA cash flows to next-generation biomaterials.

Medium-viscosity cement captured 44.65% revenue in 2025, serving as the workhorse for hip and knee arthroplasty. High-viscosity grades are forecast to expand at a 6.88% CAGR on evidence that leakage drops from 37.5% to 15% in vertebroplasty. Surgeons appreciate its dough-like handling and lower injection pressures, boosting operative confidence in spine cases. Low-viscosity mixes still earn favor for deep cancellous infiltration, though their declining usage mirrors heightened risk aversion.

Market education campaigns spotlight mechanical strength retention even after refrigeration-based working-time extensions. At the same time, fast-setting formulas shave theatre time by three to five minutes without sacrificing compressive endurance. Collectively, viscosity-specific innovations broaden surgeon toolkits, making the bone cement market more segmented and tailored to procedural nuance.

Complete Report Scope:

• By Product Type
  • Polymethyl Methacrylate (PMMA) Cement
  • Calcium Phosphate Cement
  • Glass Polyalkenoate Cement
  • Calcium-Sulphate-Based Cement
• By Viscosity
  • Low Viscosity
  • Medium Viscosity
  • High Viscosity
• By Application
  • Arthroplasty
    • Total Knee Arthroplasty
    • Total Hip Arthroplasty
    • Total Shoulder Arthroplasty
  • Vertebroplasty
  • Kyphoplasty
  • Trauma & Fracture Repair
  • Others
• By End-User
  • Hospitals
  • Orthopaedic Clinics
  • Ambulatory Surgical Centres
  • Speciality Spine Centres
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 41.05% of 2025 revenue, with high procedure density, favorable reimbursement, and early adoption of antibiotic-rich blends anchoring sales. Major integrated delivery networks lock multi-year contracts with incumbent vendors, which stabilizes baseline demand even as cementless implants nibble at the younger-patient tier. Numerous state and federal initiatives targeting opioid-sparing postoperative protocols also fuel wider elective-surgery throughput, reinforcing cement volumes.

Europe remains the second-largest cluster, characterized by stringent MDR compliance that pushes suppliers to furnish more real-world evidence. Germany, France, and the United Kingdom collectively represent over half of regional consumption, but Eastern European markets now post double-digit value growth as private hospital chains modernize orthopedic suites. Pan-EU procurement alliances increasingly evaluate life-cycle cost, thereby bolstering the shift to antibiotic-loaded and high-viscosity variants that promise lower revision rates.

Asia-Pacific holds the fastest 6.95% CAGR outlook as China, Japan, and India dramatically scale joint-replacement capacity. Government insurance expansion, rising osteoporosis prevalence, and medical-tourism corridors in Thailand and Malaysia underpin multi-year tailwinds. The region’s surgical-volume surge gradually narrows the bone cement market size gap with Western peers while inviting local entrants that focus on cost-sensitive yet clinically validated PMMA blends. Collectively, these dynamics keep the bone cement market on a geographically diversified growth path.

List of Companies Covered in this Report:

• Stryker
• Zimmer Biomet
• Johnson & Johnson
• Smiths Group
• Heraeus Holding
• Arthrex
• DJO Global
• Exactech
• Merck KGaA (Palacos)
• Cardinal Health
• Medtronic
• Beckton Dickinson
• AAP Implantate
• Tecres S.p.A.
• G21 S.r.l.
• Teknimed
• Orthofix
• Seikagaku Corp.
• Cook Group
• Synimed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support